Euroapi Revises Down Its Revenue Forecast for 2025
Euroapi, a manufacturer of active pharmaceutical ingredients, announced on December 16 that it is revising its annual outlook amid a deteriorating economic environment. Concurrently, its main shareholders Sanofi and Bpifrance have agreed to extend their shareholding commitment until December 2026.
Revenue Forecast Adjustment
According to the press release issued by the company, the revenue for the fiscal year 2025 is expected to decline within a single-digit range on a comparable basis. This revision represents a downturn compared to the previous estimate which anticipated a moderate, low single-digit decrease. The company attributes this change to a deteriorating global economic environment, without specifying further the factors involved. Euroapi employs about 3,270 people and operates five production sites in Europe, supplying around 200 active ingredient references to clients in over 80 countries.
Maintaining Core EBITDA Margin Goals
Despite the downward revision of its revenue, the group indicates that it maintains its Core EBITDA margin target for 2025 within a range of 7% to 9%. According to the company, this target remains achievable through effective cost reduction measures implemented across the organization. Euroapi emphasizes the increased efficiency of these cost reductions as part of the progress of the strategic plan FOCUS-27. The company specifies that it is currently assessing the implications of an evolving economic environment and will provide further information during the announcement of its annual results for 2025, scheduled for March 3, 2026.
Shareholder Commitment Extension
The two main shareholders of Euroapi, the pharmaceutical group Sanofi and the public institution Bpifrance, have agreed to extend the period for holding their stakes until December 18, 2026, subject to customary exceptions. According to the press release, this extension aims to strengthen the stability of the shareholder structure in the context of executing the FOCUS-27 plan. Euroapi, which separated from Sanofi during an IPO, is listed on Euronext Paris. The group will also publish its results for the first half of 2026 on July 28, and its general meeting will be held on May 27, 2026.
